Cipla Secures Exclusive License for Rolditamig Deuderuxtecan in Emerging Markets
Cipla and Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing Pharmaceutical Group, have entered an exclusive license and supply agreement for Rolditamig Deuderuxtecan (TQB2102), a HER2 bispecific antibody-drug conjugate. Cipla will develop, regulate, and commercialize the drug in India, South Africa, and five other emerging markets, while CTTQ will manufacture and supply it. TQB2102 shows promising clinical potential in treating HER2-low advanced breast cancer, combining SBP Group's oncology expertise with Cipla's market presence to accelerate patient access.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (52/100). Lens Score 41/100.
Outlets measured: businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–55/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 31 Aug, 12:54 pm. Other outlets followed.